Poly(ADP-ribose)polymerase 1 (PARP-1) inhibitors are thought as breakthrough for cancer treatment in solid tumors such as breast cancer through their effects on PARP's enzymatic activity. Our previous findings showed that the hydrophilic PARP inhibitor PJ34 enhances the sensitivity of p53 proficient MCF7 breast carcinoma cells to topotecan, a DNA Topoisomerase I (TOP 1) inhibitor. In the present study, we combine the classical TOP 1 poison camptothecin or its water-soluble derivative topotecan with PJ34 to investigate the potentiation of chemotherapeutic efficiency in MCF7 (p53(WT)), MDA-MB231 (p53(mut)) breast carcinoma cells and SCC022 (p53(null)) squamous carcinoma cells.
p63 involvement in poly(ADP-ribose)polymerase 1 signaling of Topoisomerase 1 –dependent DNA damage in carcinoma cells / Montariello, Daniela; Troiano, Annaelena; Malanga, M; Calabro', Viola; Quesada, PIERINA MARIA. - In: BIOCHEMICAL PHARMACOLOGY. - ISSN 0006-2952. - 85:7(2013), pp. 999-1006. [10.1016/j.bcp.2013.01.019]
p63 involvement in poly(ADP-ribose)polymerase 1 signaling of Topoisomerase 1 –dependent DNA damage in carcinoma cells.
MONTARIELLO, DANIELA;TROIANO, ANNAELENA;CALABRO', VIOLA;QUESADA, PIERINA MARIA
2013
Abstract
Poly(ADP-ribose)polymerase 1 (PARP-1) inhibitors are thought as breakthrough for cancer treatment in solid tumors such as breast cancer through their effects on PARP's enzymatic activity. Our previous findings showed that the hydrophilic PARP inhibitor PJ34 enhances the sensitivity of p53 proficient MCF7 breast carcinoma cells to topotecan, a DNA Topoisomerase I (TOP 1) inhibitor. In the present study, we combine the classical TOP 1 poison camptothecin or its water-soluble derivative topotecan with PJ34 to investigate the potentiation of chemotherapeutic efficiency in MCF7 (p53(WT)), MDA-MB231 (p53(mut)) breast carcinoma cells and SCC022 (p53(null)) squamous carcinoma cells.File | Dimensione | Formato | |
---|---|---|---|
Montariello 2013 Biochem Pharm..pdf
solo utenti autorizzati
Descrizione: Articolo principale
Tipologia:
Documento in Pre-print
Licenza:
Accesso privato/ristretto
Dimensione
561.81 kB
Formato
Adobe PDF
|
561.81 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.